A significant proportion of those with<unk>  will experience a life-threatening abnormal heart rhythm, with estimates of this risk ranging from 13-20% over the course of 7–8 years. Life-threatening arrhythmias are more likely to occur if<unk>  has been diagnosed in childhood, if a person with<unk>  does not take beta blockers, and if arrhythmias occur on exercise testing despite taking beta blockers. During treatment with nadolol, the preferred beta blocker for the treatment of<unk> , event rates have been estimated to be 0.8% per year. In patients treated with beta blockers, life-threatening arrhythmias are more likely if a person had already survived a cardiac arrest, had a syncope, or are carriers of disease-causing mutations affecting the highly conserved terminal portion of RYR2 gene, called the C-terminal domain (amino acids 4889-4969).
Catecholaminergic polymorphic ventricular tachycardia
Benign early repolarization
Junctional ectopic tachycardia
Brugada syndrome
Pre-excitation syndrome
Long QT syndrome
Wandering atrial pacemaker
Andersen–Tawil syndrome